Looks like they got the notice on December 6th so they have until June 5th to meet the minimum bid requirement. If they can't do it by then they may get another extension (see criteria below). Nonetheless, Nora Pharma needs to get busy to bolster up SBFM with some excellent news about how much more revenue they will be generating and the timeline for the Biosimilar getting approval at least by Health Canada. Then they need to expand into the US as soon as possible and add the SBFM anti-cancer treatment. Six months isn't a long time, but should be enough to get some headlines that have substance.
From the recent SEC filing Form 8K: Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On December 6, 2022, Sunshine Biopharma, Inc. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company no longer meets the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). The notification has no immediate effect on the listing of the Company’s common stock. In accordance with Nasdaq Marketplace Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from December 6, 2022, or until June 5, 2023, to regain compliance with the Minimum Bid Price Requirement. If at any time before June 5, 2023, the bid price of the Company’s common stock closes at or above $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the Minimum Bid Price Requirement. The notification letter also disclosed that in the event the Company does not regain compliance with the Minimum Bid Price Requirement by June 5, 2023, the Company may be eligible for additional time. To qualify for additional time, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days to regain compliance. However, if it appears to the staff of Nasdaq (the “Staff”) that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, the Staff would notify the Company that its securities will be subject to delisting.
The Company intends to continue actively monitoring the bid price for its common stock between now and June 5, 2023 and will consider available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement.
AI
